再普乐是礼来公司的最畅销的药物。
2002年,礼来的再普乐在日本上市仅10个月后,该国的卫生官员就要求礼来公司警告医师不要对糖尿病人开再普乐。
And in 2002, only 10 months after Lilly began selling Zyprexa in Japan, medical regulators in that country required Lilly to warn doctors against using Zyprexa in diabetic patients.
直到2007年礼来公司才在再普乐的标签中增加了反映药物有导致体重明显增加和血糖改变的趋势的严重警告。
Lilly waited until 2007 to add strong warnings to Zyprexa's label to reflect the drug's tendency to cause severe weight gain and blood sugar changes.
应用推荐